FDA approves “Moderna vaccine” in adolescents 12-17 years old, same form as adults, use 2 doses 28 days apart
Today (16 Sept. 20)Ms. Sunaina agricultural affairs General Manager, ZP Therapy, Zillic Pharma Thailand, revealed that the Food and Drug Administration (FDA) has increased approval for the COVID-19 vaccine in young people. Age 12-17 years in Thailand, with the same vaccination pattern as the adult injection, which is 2 injections, with the second injection 28 days from the first dose.
The approval of the use of the Covid-19 vaccine for adolescents It is considered to increase the potential of the COVID-19 vaccine. that Thailand can use to combat the epidemic situation
“The Company is very pleased that FDA approved the use of the COVID-19 vaccine Moderna for young people in order to have a shield against the corona virus Especially in a situation where the delta strain continues to be highly contagious…if we can support vaccination to cover more people? The faster the group immunity will be driven. It will also help the country return to normal faster in the end,” said Ms Sunaina.
It said that in May 64, Moderna announced the results of a Phase 2/3 clinical study of the Covid-19 Moderna vaccine in adolescents (Phase 2/3 TeenCOVE study). has been successful in building immunity Equivalent to vaccine immunization among adults Two doses of the COVID-19 Moderna vaccine were shown to be 100% effective in preventing symptomatic infection among adolescents aged 12-17 years, and were effective in both safety and response. The vaccine responded to the same level as the results of a Phase 3 clinical trial in adults (Phase 3 COVE study). and continues to monitor research results from independent safety monitoring committees. These data are subject to change depending on the results of additional data collection.
